Adel Nada, GentiBio CEO

At an 'in­flec­tion point': Gen­tiBio reels in $157M ahead of what CEO Adel Na­da sees as a Treg boom

Gen­tiBio CEO Adel Na­da says reg­u­la­to­ry T cells (or Tregs) are now where CAR-Ts were at the be­gin­ning of the last decade — at an in­flec­tion point. With a hand­ful of drug­mak­ers ze­ro­ing in on the pro­tec­tive class of im­mune cells, Na­da says big de­vel­op­ments are com­ing. And the proof, he says, is in his com­pa­ny’s lat­est megaround.

Na­da un­veiled a $157 mil­lion Se­ries A round on Wednes­day morn­ing from some big-name back­ers like the No­var­tis Ven­ture Fund and RA Cap­i­tal Man­age­ment. With a raise like that, it’s hard to imag­ine that a pub­lic de­but is too far down the road for Gen­tiBio.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.